Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-08
2011-03-08
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S311000, C546S143000, C546S171000
Reexamination Certificate
active
07902224
ABSTRACT:
The present invention is directed to compounds of formula (I):whereinR represents a methyl or an ethyl groupX represents N, C—H or C—CH3when X represents C—H or C—CH3, Y represents Nwhen X represents N, Y represents C—Hand physiologically functional derivatives thereof, pharmaceutical compositions comprising the compounds, the use of the compounds for the manufacture of medicaments particularly for the treatment of inflammatory and/or allergic conditions, processes for the preparation of the compounds, and chemical intermediates in the processes for the manufacture of the compounds.
REFERENCES:
patent: 10261874 (2004-07-01), None
patent: 0439265 (1991-07-01), None
patent: 0032584 (2000-06-01), None
patent: WO 00/34243 (2000-06-01), None
patent: 0142193 (2001-06-01), None
patent: 0210143 (2002-02-01), None
patent: 02066422 (2002-08-01), None
patent: 02070490 (2002-09-01), None
patent: 02076933 (2002-10-01), None
patent: 03024439 (2003-03-01), None
patent: 03042160 (2003-05-01), None
patent: 03072539 (2003-09-01), None
patent: 03082280 (2003-10-01), None
patent: WO 03/082827 (2003-10-01), None
patent: 03091204 (2003-11-01), None
patent: 2004016578 (2004-02-01), None
patent: 2004022547 (2004-03-01), None
patent: 2004037768 (2004-05-01), None
patent: 2004037773 (2004-05-01), None
patent: 2004037807 (2004-05-01), None
patent: 2004039762 (2004-05-01), None
patent: 2004039766 (2004-05-01), None
patent: WO 2004/063163 (2004-07-01), None
patent: WO 2004/071389 (2004-08-01), None
patent: 2005003098 (2005-01-01), None
patent: 2005030213 (2005-04-01), None
patent: 2005044354 (2005-05-01), None
Allen, D.B.; Do intranasal cortisosteriods affect childhood growth?; Allergy; 2000; 62; 15-18.
Andrews, et al.; Glucocorticoids and insulin resistance: old hormones, new targets; Clinical Science; 1999; 96; 513-523.
Austin et al; Mometasone furoate is a less specific glucocorticoid than fluticasone propionate; European Respiratory Journal; 2002; 20; 1386-1392.
Barnes and Adcock; Anti-inflammatory actions of steroids: molecular mechanisms; TiPS; Dec. 1993; 14; 436-441.
Cato and Wade; Molecular mechanisms of anti-inflammatory action of glucocorticoids; BioEssays; 1996; 18/5; 371-378.
Cumming et al; Use of inhaled corticosteroids and the risk of cataracts; The New England Journal of Medicine; 1997; 337/1; 8-14.
Faul et al; High dose inhaled corticosteroids and dose dependent loss of diabetic control; BMJ; 1998; 317; 1491.
Fujii et al; Novel phosphodiesterase 4 inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen; The Journal of Pharmacology and Experimental Therapeutics; 1998; 28/1; 162-169.
Hartley and McKiernan; Titanium reagents for the alkylidenation of carboxylic acid and carbonic acid derivates; Journal of the Chemical Society—Perkin Transactions I; 2002; 2763-2793.
Hibino et al; Carbonyl methylenation of easily enolizable ketones; Tetrahedron Letters; 1985; 26/45; 5579-5580.
Pauwels et al; Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking; The New England Journal of Medicine; 1999; 340/25; 1948-1953.
Ray et al; Anti-inflammation: Direct physical association and functional antagonism between transcription factor NF-KB and the glucocorticoid receptor; Chest; 1995; 107/3; 1395.
Ray et al; Induction of the e-selection promoter by interleukin 1 and tumor necrosis factor a, and inhibition by glucocorticoids; Journal of Biochemistry; 1997; 320; 707-715.
Schacke et al; Mechanisms involved in the side effects of glucocorticoids; Pharmacology & Therapeutics; 2002; 96; 23-43.
Wong et al; Inhaled corticosteroid use and bone-mineral density in patients with asthma; The Lancet; 2000; 335; 1399-1403.
Elinson et al; Electrocatalytic transformation of malononitrile and cycloalkylidenemalononitriles into spirobycyclic and spirotricyclic compounds containing 1,1,2,2-tetracyanocyclopropane fragment; Russian Chemical Bulletin; 2003; 52/10; 2235-2240.
Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, XP002358363, BRN: 1961178, abstract.
Sole et al., “Intramolecular pd-mediated processes of amino-tethered aryl halides and ketones: Insight into the ketone.alpha.-arylation and carbonyl-addition dichotomy. A new class of four-membered azapalladacycles,”Journal of the American Chemical Society125(6):1587-1594 (2003).
Edwards Christine
Fenton Garry
MacDonald Simon John Fawcett
Weingarten Gordon Gad
Davis Zinna N
Glaxo Group Limited
Smith Robert J.
LandOfFree
Tetrahydro-naphthalene derivatives as glucocorticoid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydro-naphthalene derivatives as glucocorticoid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydro-naphthalene derivatives as glucocorticoid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2720411